Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tafinlar dabrafenib: Interim Phase I/II data

Interim data from 36 mCRC patients with V600 BRAF mutations in an open-label, U.S. and Australian Phase I/II trial showed that twice-daily 150 mg Tafinlar plus once-daily 2 mg Mekinist trametinib

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers